ライフサイエンスコーパス: primary lung cancer

1 tatus of brain metastases, and the status of primary lung cancer.

2 umab may be a therapeutic drug candidate for primary lung cancer.

3 sometimes required to distinguish them from primary lung cancer.

4 eveloping pulmonary metastases and/or second primary lung cancer.

5 hy for diagnosing lung metastases and second primary lung cancer.

6 ng disease, fatal respiratory infection, and primary lung cancer.

7 nts treated with RFA for lung metastases and primary lung cancers.

8 years and then annually for detection of new primary lung cancers.

9 d are lost together in cancer cell lines and primary lung cancers.

10 cancers which we have confirmed in 40 other primary lung cancers.

11 that lack of gene expression also occurs in primary lung cancers.

12 and human mutT, were abundantly expressed in primary lung cancers (10 of 18, 15 of 18, and 6 of 12 tu

13 214 LNs from 105 patients with 100 primary lung cancers, 2 occult primary lung tumors, and

14 ne of 137 patients (6.5%) developed a second primary lung cancer (6 patients) or lung metastases (3 p

15 nts, 1257 (1.4%) were diagnosed with a first primary lung cancer (684 male, 573 female; median age, 6

16 All instances of first diagnosis of primary lung cancer after a negative screening result 7-

17 nt ages at diagnoses: age 40 to 49 years for primary lung cancer; age 50 to 59 years for primary mela

18 ay have comparable efficacy in detecting new primary lung cancer among stage I NSCLC survivors after

19 omen; age range, 49-82 years) with untreated primary lung cancer and 17 women with untreated primary

20 The subjects were 89 cases of primary lung cancer and 173 controls, all males, matched

21 rs to be promising as a prognostic factor in primary lung cancer and as a noninvasive tumor marker in

22 on of the Fus1 protein was observed in human primary lung cancer and cancer cell lines.

23 c measures, there are 27 diseases (including primary lung cancer and diabetes) where the hazard ratio

24 culosis, to community acquired pneumonia and primary lung cancer and healthy controls, before and aft

25 Fifty-six chest radiographs of 34 primary lung cancers and 22 benign nodules were digitize

26 fty-three chest radiographs that depicted 31 primary lung cancers and 22 benign nodules were used.

27 Low or undetectable NEP is present in many primary lung cancers and cell lines.

28 ated with overexpression of these targets in primary lung cancers and coincided with DNA methylation,

29 he PGP9.5 transcript was highly expressed in primary lung cancers and lung cancer cell lines but was

30 ve shown that PGP9.5 was highly expressed in primary lung cancers and lung cancer cell lines.

31 were sequence analyzed from two independent primary lung cancers and two normal human bronchial/trac

32 as PC (39 proven, 37 highly probable), 7 as primary lung cancer, and 2 as activated tuberculosis; 4

33 between 2014 and 2017 prior to lobectomy for primary lung cancer at three institutions.

34 cohort design, we evaluated 587 patients of primary lung cancer at two tertiary care facilities.

35 oaxial lung core-needle biopsy for suspected primary lung cancer between November 2012 and August 202

36 s, was significantly increased (5.7-fold) in primary lung cancers but not adjacent tissues.

37 ARgamma protein was also expressed in 50% of primary lung cancers by immunohistochemistry.

38 studied in paraffin sections from untreated primary lung cancers by immunohistochemistry.

39 LC), along with a surgical resection for the primary lung cancer, can be curative.

40 Primary lung cancer cases (n = 2,101) were recruited fro

41 Furthermore, primary lung cancer cells derived from patients with hyp

42 ONYX-015 lysed primary lung cancer cells in six of seven (86 %) primary

43 Primary lung cancer cells isolated from patient lung tum

44 increased apoptosis of cancer cell lines and primary lung cancer cells, and attenuated endothelial ce

45 al lung cancer cell lines and drug-resistant primary lung cancer cells.

46 essive therapy, the most likely culprits are primary lung cancer, chronic infectious or inactive gran

47 patients aged 40 years or older with a first primary lung cancer diagnosis and 4606 matched controls

48 ases were identified from patients who had a primary lung cancer diagnosis between 2012 and 2019; con

49 gs of 13 patients due to undergo surgery for primary lung cancer (five of 13) or spontaneous pneumoth

50 (ACBD3), a Golgi resident protein, promotes primary lung cancer growth by recruiting phosphatidylino

51 dose CT screening and diagnosed with a first primary lung cancer has persisted, as shown by the updat

52 374 uveal metastatic tumors originating from primary lung cancer in 229 eyes of 194 patients.

53 f uveal metastasis preceded the diagnosis of primary lung cancer in 44% of patients.

54 116 of 496 patients (23.4%), including a new primary lung cancer in 77 of 496 patients (15.5%) and NL

55 during the development of chemically induced primary lung cancer in mice.

56 A 5% rate of stage I primary lung cancer in patients selected for lung volume

57 te reliably between pulmonary metastases and primary lung cancer in PC patients.

58 FDG PET led to a biopsy-proved diagnosis of primary lung cancer in two patients.

59 arker of prenatal sex steroids exposure) and primary lung cancer in women and men.

60 ung cancer (SPLC) among survivors of initial primary lung cancer (IPLC) and evaluated the clinical ut

61 mproved survival among patients with initial primary lung cancer (IPLC), who are now at high risk of

62 nd lesions of different origin, for example, primary lung cancer, is a common clinical question.

63 edictive symptoms/sensations attributable to primary lung cancer (LC).

64 issue, RSK1 was reduced in metastatic versus primary lung cancer lesions.

65 tiple lung cancers to differentiate multiple primary lung cancers (MPLCs) from pulmonary metastases.

66 y lesions, including metastases (n = 38) and primary lung cancers (n = 44), underwent RFA.

67 The most important mortality predictors were primary lung cancer (odds ratio: 1.73, 95% confidence in

68 inical trial, study participants with either primary lung cancer or pulmonary metastases were enrolle

69 he derivation of these tumors, either as new primary lung cancers or as metastatic head and neck canc

70 Three patients had synchronous primary lung cancers or multifocal disease.

71 cal, regional, or distant recurrence; second primary lung cancer; or death).

72 /- 3.9 for PC metastases and 5.6 +/- 1.6 for primary lung cancer (P = 0.408).

73 metastases recurred less often than treated primary lung cancers (P = 0.03).

74 Primary lung cancer remains the leading cause of cancer-

75 imated the 10-year risk of developing second primary lung cancer (SPLC) among survivors of initial pr

76 resection are at risk for developing second primary lung cancer (SPLC).

77 ho are now at high risk of developing second primary lung cancer (SPLC).

78 ng cancer) and expression of DeltaDNMT3B4 in primary lung cancer, suggesting a role of DeltaDNMT3B in

79 urvival of participants diagnosed with first primary lung cancer through annual low-dose CT screening

80 urvival of participants diagnosed with first primary lung cancer through annual low-dose CT screening

81 for 484 participants diagnosed with a first primary lung cancer through annual screening, with a hig

82 cancer, breast cancer, and mesothelioma) and primary lung cancer tissue samples.

83 d in the lung and is down-regulated in human primary lung cancer tissues and cell lines.

84 etected methylation of APC in 95 of 99 (96%) primary lung cancer tissues.

85 We evaluated primary lung cancers, tumor cell lines, and preneoplasti

86 Primary lung cancer tumors in 21 patients were measured

87 emission tomography (PET) scans obtained in primary lung cancer tumors.

88 adenocarcinomas and other non-neuroendocrine primary lung cancer types in the right upper lobe.

89 n cancer survivorship and the risk of second primary lung cancer underscores both the challenges and

90 The likelihood of a primary lung cancer versus a metastasis depends on the h

91 four analyzable patients who had surgery for primary lung cancer were included.

92 Between 2002 and 2005, 2,100 patients with primary lung cancer were recruited from 13 hospitals wit

93 Eighty-three primary lung cancers were found during an annual low-dos

94 e, the results of the five cases, except for primary lung cancer, were consistent.

95 Primary lung cancers with microsatellite alterations at

96 lays), of which four received a diagnosis of primary lung cancer within the subsequent 2 years.